Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Louis-Marie Dourthe is active.

Publication


Featured researches published by Louis-Marie Dourthe.


Journal of Clinical Oncology | 2015

Raltitrexed in the management of metastatic colorectal cancer: The COMET study.

Jérôme Desramé; Louis-Marie Dourthe; Philippe Debourdeau; Dominique Mille; Pascal Artru; Hélène Albrand

677 Background: Raltitrexed, indicated for palliative treatment of advanced colorectal cancer (CRC), may be useful for patients (pts) with cardiovascular (CV) risk factors, or cardiotoxicity/disease progression with prior chemotherapy (CT). The COMET study, conducted in France, described the characteristics of pts with metastatic CRC (mCRC) treated with raltitrexed, focusing on pts with cardiotoxicity or disease progression with prior 5-fluorouracil (5FU)/folinic acid. Methods: A national, multicentred, cross-sectional, non-interventional study to describe the profiles of pts with mCRC treated with raltitrexed. Pts (≥18 years) with mCRC, treated with raltitrexed as a single agent or in combination therapy, were included. Following patient consent, retrospective data were recorded during a single inclusion visit based on pt medical files; during the study, data were recorded prospectively. Results: 414 pts with mCRC were analysed; 84.8% had ≥1 prior CT, 60.9% had CV risk factors and 35.2% had CV history (a...


Gastroenterologie Clinique Et Biologique | 2006

La fréquence du syndrome hémolytique et urémique secondaire à la gemcitabine est-elle sous-estimée ? : Intérêt d'un dépistage sytématique

Jérôme Desramé; Christian Duvic; Dominique Bechade; Christian Bredin; Jean Jacques Raynaud; G. Defuentes; Louis-Marie Dourthe; J.-P. Algayres


Revue de Médecine Interne | 1999

Encéphalopathie à l'ifosfamide. À propos de deux cas

Louis-Marie Dourthe; Gilles Coutant; J. Desramé; Jacques Merrer; Jp Daly


Journal of Clinical Oncology | 2017

Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study.

Michel Ducreux; Leopold Öhler; Werner Scheithauer; Jean-Philippe Metges; Louis-Marie Dourthe; Jan de Groot; J. Thaler; Kun-Huei Yeh; Jen-Kou Lin; Alfredo Falcone; Cornelis J. A. Punt; Ann M. Contijoch; Sabine Fiala-Buskies; Andres Cervantes-Ruiperez; J O’Connor


Journal of Clinical Oncology | 2018

Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

Antoine Thiery Vuillemin; Mads Hvid Poulsen; Louis-Marie Dourthe; Redas Trepiakas; Edouard Lagneau; Elias Pasquale Pintus; Dominique Beal-Ardisson; Alison J. Birtle; Guillaume Ploussard; Hervé Besson; Martin Lukac; Paul Robinson; Alison Reid


Journal of Clinical Oncology | 2017

Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.

Michel Ducreux; Leopold Öhler; Werner Scheithauer; Jean-Philippe Metges; Louis-Marie Dourthe; Jan de Groot; Josef Thaler; Kun-Huei Yeh; Jen-Kou Lin; Alfredo Falcone; Cornelis J. A. Punt; Jan Kalinovsky; Sabine Fiala-Buskies; A. Cervantes; Juan Manuel O'Connor


Annals of Oncology | 2017

PD-025Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study

Manuel O’Connor Juan; Leopold Öhler; Werner Scheithauer; Jean-Philippe Metges; Louis-Marie Dourthe; Willem de Groot Jan; Josef Thaler; Kun-Huei Yeh; Jen-Kou Lin; Alfredo Falcone; Punt Cornelis J A; Jan Kalinovsky; Sabine Fiala-Buskies; A. Cervantes; Petersen Lone N; Michel Ducreux


Journal of Clinical Oncology | 2016

Bevacizumab plus chemotherapy (bev/CT) as first-line therapy for patients with potentially resectable metastatic colorectal cancer (mCRC): Final results of the French noninterventional PICASSO study.

David Malka; Jean-Philippe Metges; Dominique Elias; Jaafar Bennouna; Franck Bonnetain; Louis-Marie Dourthe; Meher Ben Abdelghani; Abderraouf Radji; Philippe Laplaige; Fabien Petit Laurent; Vanessa Barue; Sophie Gandon; Michel Rivoire


Annals of Oncology | 2016

PD-032Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study

J.-P. Metges; J. Bennouna; Michel Rivoire; Dominique Elias; Franck Bonnetain; Louis-Marie Dourthe; M. Ben Abdelghani; R. Radji; Philippe Laplaige; F. Petit Laurent; K. Sébastien; J. Telliez; David Malka


Journal of Clinical Oncology | 2015

Aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: First interim safety data from AFEQT trial.

Meher Ben Abdelghani; Christophe Borg; Louis-Marie Dourthe; Gael Deplanque; Julien Taieb; Jean-Philippe Metges; Philippe Laplaige; Veronique Lotz; Amele Amrate; Gérard Lledo

Collaboration


Dive into the Louis-Marie Dourthe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christian Duvic

École pratique des hautes études

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Werner Scheithauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Jen-Kou Lin

Taipei Veterans General Hospital

View shared research outputs
Top Co-Authors

Avatar

Kun-Huei Yeh

National Taiwan University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Malka

Institut Gustave Roussy

View shared research outputs
Researchain Logo
Decentralizing Knowledge